Gentian Diagnostics ASA (GENT.XOSL) DCF Valuation
Every assumption below is yours to change. The defaults are derived from this company's own filing history, not from a house view.
Conservative
kr 14.44
315% undervaluedvs kr 3.48
Base
kr 17.45
401% undervaluedvs kr 3.48
Optimistic
kr 20.95
502% undervaluedvs kr 3.48
Where today's price sits
Today's price falls outside the modelled range.
Verdict
Today's price sits below all three scenarios. Under these assumptions the stock looks undervalued, which is only as reliable as the growth rates you have entered.
Base free cash flow
kr 13M
Trailing twelve months
Historical FCF CAGR
+5.5%
Across 6 reported periods
Market implies
—
No solution in range
Terminal value share
60%
Of the base case valuation
Growth needed to justify today's price
No growth rate in the tested range reproduces today's price at these assumptions.
Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.
Free cash flow history
The most recent period is the base every projection starts from. Compounded, that history is +5.5% a year.
Gentian Diagnostics ASA (GENT.XOSL) DCF: intrinsic value and margin of safety
Intrinsiqq's two-stage DCF values Gentian Diagnostics ASA (GENT.XOSL) at about NOK 23.23 per share, or NOK 17.43 with a 25% margin of safety. At NOK 3.48 the stock looks undervalued. Every assumption is adjustable below; this is analysis, not investment advice.
Frequently asked
What is Gentian Diagnostics ASA's (GENT.XOSL) fair value?+
Intrinsiqq's two-stage discounted cash flow (DCF) model estimates an intrinsic value of about NOK 23.23 per share for GENT.XOSL. It projects recent free cash flow forward at a growth rate that fades toward a long-run rate, then discounts those cash flows back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 17.43. The output moves with the growth and discount-rate inputs, so it is best read as a range, not a single number. You can change every assumption with the sliders on this tab.
Is Gentian Diagnostics ASA overvalued based on a DCF?+
At NOK 3.48, GENT.XOSL trades below the base-case intrinsic value of about NOK 23.23, a 567.7% discount to that estimate, so on this model it looks undervalued. A DCF is only one lens: a premium can be justified if the business grows faster or is higher quality than the base case assumes, which is exactly what the sliders let you test.
What growth is priced into Gentian Diagnostics ASA?+
The base case grows GENT.XOSL's free cash flow at about 5.5% a year before fading, against roughly 5.5% historical free-cash-flow growth. If the price implies growth well above what the company has actually delivered, the market is paying for optimism; if below, expectations are modest. Adjust the growth assumption on this tab to see what the current price is really betting on.
What is a good margin of safety for Gentian Diagnostics ASA?+
A margin of safety is the discount to intrinsic value you demand before buying, to protect against being wrong on the inputs. Intrinsiqq applies 25% by default, which turns GENT.XOSL's NOK 23.23 intrinsic estimate into a NOK 17.43 entry. Wider margins suit less predictable businesses; you can set your own on this tab. This is analysis from company filings, not investment advice.
Related stocks: Medical Devices
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.